18-8 : Dexmedetomidine use in patients with 33℃ targeted temperature management-focused on bradycardia as an adverse effect

Introduction: This study’s aimed to investigate bradycardia after dexmedetomidine infusion during 33℃ target temperature management. Material & Methods: A retrospective study’s conducted on patients underwent 33℃ target temperature management. We collected data including age, sex, weight, diagnosis, bradycardia occurrence, target temperature management duration, sedative drug, and several clinical and laboratory results. We conducted logistic regression for an analysis of factors associated bradycardia. Results: A total of 85 patients were selected, of which 17 were excluded. Among 68 patients, 39 showed bradycardia, 56 were administered with dexmedetomidine. Odds ratio for bradycardia of CO poisoning group over cardiac arrest group and for weight (kg) were 7.448 (95% CI 1.834-30.244, p=0.005) and 1.058 (95% CI 1.002-1.123, p=0.044) respectively. In the bradycardia group with dexmedetomidine, infusion rate of dexmedetomidine was 0.41±0.15 (μg/kg/h). Decisions of charged doctor’s were 1) slowing infusion rate 2) stopping infusion or giving atropine. All cases need no cardiac pacing and didn’t worsen to asystole. Conclusion: Despite of the frequency, bradycardia was recovered after reducing infusion rate. However, lowering infusion rate of dexmedetomidine should be needed to prevent bradycardia from developing in patients with heavy weight, CO poisoning during 33℃ targeted temperature management.